The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
Open accessAbstract
Class I phosphatidylinositol 3 kinases (PI3K) phosphorylate phosphatidylinositol 4,5‐bisphosphate to generate phosphatidylinositol 3,4,5‐trisphosphate. These molecules play an important role in fundamental cellular responses. Four isoforms of class I PI3K are known to have different functions, and abnormalities in their activities have been related to various diseases such as cancer and inflammation. We previously identified a novel PI3K inhibitor, ZSTK474, which showed potent antitumor activity in vivo against a human cancer xenograft without observable toxicity. However, the mode of its molecular action was not investigated in detail. Our previous study only suggested that ZSTK474 possibly competes with ATP for the ATP‐binding pocket of PI3Kγ. In the present study, we have used an in vitro homogenous time‐resolved fluorescence kinase assay to examine whether ZSTK474 is indeed an ATP‐competing inhibitor of PI3K, and also to determine whether the inhibitory activity of ZSTK474 was isoform‐specific. Lineweaver–Burk plot analysis revealed that ZSTK474 inhibits all four PI3K isoforms in an ATP‐competitive manner. Among all of the PI3K isoforms, PI3Kδ was inhibited most potently by ZSTK474 with a K i of 1.8 nM, and the other isoforms were inhibited at higher doses. We have also used a kinase activity ELISA to determine whether ZSTK474 inhibits mammalian target of rapamycin, a key kinase acting downstream of PI3K to promote protein synthesis and cell proliferation. Even at a concentration of 100 µM, ZSTK474 inhibited mammalian target of rapamycin activity rather weakly. These results indicate that ZSTK474 is an ATP‐competitive pan‐class I PI3K inhibitor. (Cancer Sci 2007; 98: 1638–1642)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953
Cited by
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Kourounakis, A. P., Xanthopoulos, D., & Tzara, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21634 · Cited by 294
Metadata
- Authors
- Kong, D., & Yamori, T.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2007-08-16
- Volume
- 98
- Issue
- 10
- Pages
- 1638-1642
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2083894326
- Cited by
- 166
- References
- 1
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. https://app.cochat.ai/papers/10.1111/j.1349-7006.2007.00580.x
- The paper
- Kong, D., & Yamori, T. (2007). ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Science. https://doi.org/10.1111/j.1349-7006.2007.00580.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.